Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05817929

Angiopoietin and Adverse Outcomes in Cardiac Surgery

Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery.

The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiac Surgery Acute Kidney Injury Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult patient scheduled for cardiac surgery under cardiopulmonary bypass

Exclusion criteria

  • patient less than 18 years old,
  • redo surgery,
  • urgent surgery,
  • endocarditis,
  • aortic root repair surgery
  • aortic dissection
  • heart beating surgery,
  • heart transplantation

Treatment and study plan

blood sample

Other

5 ml blood sample will be withdrawn at the surgery start and at the surgery end

Primary outcomes

  1. Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event

    Time frame: 28 days

    major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death

  2. correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event

    Time frame: 28 days

    major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death

Secondary outcomes

  1. Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of postoperative pulmonary complications

    Time frame: 28 days

  2. Correlation between abnormal angiopoietin 2 concentration (ng/ml) and number of postoperative pulmonary complications

    Time frame: 28 days

  3. Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 3 months

    Time frame: 3 months

  4. Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality at 3 months

    Time frame: 3 months

  5. Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 6 months

    Time frame: 6 months

  6. Correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and mortality at 6 months

    Time frame: 6 months

  7. Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality rate at 12 months

    Time frame: 12 months

  8. Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality rate at 12 months

    Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Osama ABOU ARAB, MD

CONTACT

[email protected]

03 22 08 78 36

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Official study title

Angiopoietin Dysregulation to Predict Adverse Outcomes in Cardiac Surgery: the Prospective

Acronym: ANGE

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
Apr 18, 2023
Registry last updated
May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.